207 related articles for article (PubMed ID: 12386252)
1. Treatment of secondary hyperparathyroidism with vitamin D derivatives and calcimimetics before and after start of dialysis.
Drüeke TB
Nephrol Dial Transplant; 2002; 17 Suppl 11():20-2. PubMed ID: 12386252
[TBL] [Abstract][Full Text] [Related]
2. Calcimimetics: a new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease.
Lindberg JS
Kidney Int Suppl; 2005 Jun; (95):S33-6. PubMed ID: 15882311
[TBL] [Abstract][Full Text] [Related]
3. [Calcimimetic agents in the treatment of hyperparathyroidism secondary to chronic renal failure].
Negri AL; Slatopolsky EA
Medicina (B Aires); 2003; 63(2):165-71. PubMed ID: 12793088
[TBL] [Abstract][Full Text] [Related]
4. Prevention of uremic bone disease using calcimimetic compounds.
Olgaard K; Lewin E
Annu Rev Med; 2001; 52():203-20. PubMed ID: 11160775
[TBL] [Abstract][Full Text] [Related]
5. Future role of calcimimetics in end-stage renal disease.
Goodman WG; Turner SA
Adv Ren Replace Ther; 2002 Jul; 9(3):200-8. PubMed ID: 12203202
[TBL] [Abstract][Full Text] [Related]
6. [Management of secondary hyperparathyroidism].
Cunningham J
Clin Calcium; 2005 Sep; 15 Suppl 1():217-24. PubMed ID: 16279027
[No Abstract] [Full Text] [Related]
7. The calcium receptor and calcimimetics.
Wada M; Nagano N; Nemeth EF
Curr Opin Nephrol Hypertens; 1999 Jul; 8(4):429-33. PubMed ID: 10491737
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of biochemical and patient-level effects of calcimimetic therapy.
Strippoli GF; Palmer S; Tong A; Elder G; Messa P; Craig JC
Am J Kidney Dis; 2006 May; 47(5):715-26. PubMed ID: 16632010
[TBL] [Abstract][Full Text] [Related]
9. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.
Strippoli GF; Tong A; Palmer SC; Elder G; Craig JC
Cochrane Database Syst Rev; 2006 Oct; (4):CD006254. PubMed ID: 17054287
[TBL] [Abstract][Full Text] [Related]
10. Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives.
Drüeke TB; Ritz E
Clin J Am Soc Nephrol; 2009 Jan; 4(1):234-41. PubMed ID: 19056615
[TBL] [Abstract][Full Text] [Related]
11. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
12. The impact of calcimimetics on mineral metabolism and secondary hyperparathyroidism in end-stage renal disease.
Block GA
Kidney Int Suppl; 2003 Nov; (87):S131-6. PubMed ID: 14531786
[TBL] [Abstract][Full Text] [Related]
13. Calcimimetics normalize the phosphate-induced stimulation of PTH secretion in vivo and in vitro.
Almaden Y; Rodriguez-Ortiz ME; Canalejo A; Cañadillas S; Canalejo R; Martin D; Aguilera-Tejero E; Rodríguez M
J Nephrol; 2009; 22(2):281-8. PubMed ID: 19384847
[TBL] [Abstract][Full Text] [Related]
14. Calcimimetic agents for the treatment of secondary hyperparathyroidism.
Goodman WG
Semin Nephrol; 2004 Sep; 24(5):460-3. PubMed ID: 15490411
[TBL] [Abstract][Full Text] [Related]
15. Calcimimetic agents: review and perspectives.
Ureña P; Frazão JM
Kidney Int Suppl; 2003 Jun; (85):S91-6. PubMed ID: 12753275
[TBL] [Abstract][Full Text] [Related]
16. Calcimimetics and hyperparathyroidism.
Krebs LJ
Curr Opin Investig Drugs; 2004 Oct; 5(10):1080-5. PubMed ID: 15535429
[TBL] [Abstract][Full Text] [Related]
17. New approaches to treatment of secondary hyperparathyroidism.
Locatelli F; Limardo M; Pontoriero G
Curr Opin Investig Drugs; 2008 Apr; 9(4):363-70. PubMed ID: 18393103
[TBL] [Abstract][Full Text] [Related]
18. Advances in pharmacotherapy for secondary hyperparathyroidism.
Rodríguez M; Rodríguez-Ortiz ME
Expert Opin Pharmacother; 2015; 16(11):1703-16. PubMed ID: 26159447
[TBL] [Abstract][Full Text] [Related]
19. [Calcimimetics, phosphate binders, vitamin D and its analogues for treating secondary hyperparathyroidism in chronic kidney disease: guideline from the Italian Society of Nephrology].
Mazzaferro S; Cozzolino M; Marangella M; Strippoli GF; Messa P;
G Ital Nefrol; 2007; 24 Suppl 37():S107-24. PubMed ID: 17347960
[TBL] [Abstract][Full Text] [Related]
20. Challenges in the therapy of secondary hyperparathyroidism.
Wood C; González EA; Martin KJ
Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
